These data suggest that inhibition of TGFβ-signaling contributes to the therapeutic efficacy of nintedanib in IPF patients, either indirectly through c-ABL and/or ERK, as hypothesized by the authors, or directly through TGFBR inhibition, as suggested by our findings. Here, ABL1 is linked to idiopathic pulmonary fibrosis.